Did you know that depression linked to asthma might not be the same as typical depression? This surprising discovery could change how we treat both conditions. Researchers from Hiroshima University in Japan, along with their collaborators, have uncovered a fascinating biological difference in adults with asthma who experience depression. They found that these individuals have higher blood levels of a protein called brain-derived neurotrophic factor (BDNF), which is usually lower in people with major depressive disorder. Published in The Journal of Allergy and Clinical Immunology: In Practice, this study sheds new light on the unique relationship between asthma and depression. But here's where it gets controversial: could treating depression in asthma patients require a completely different approach than treating depression on its own?
Depression in asthma patients is often tied to poorer asthma control and more severe symptoms. While low BDNF levels are a hallmark of major depressive disorder, this protein plays a dual role—it’s produced not only in the brain but also in the lungs. During airway inflammation, lung BDNF levels rise, affecting airway nerves and inflammatory processes. This can increase airway sensitivity and worsen asthma symptoms. And this is the part most people miss: the biological mechanisms driving depression in asthma might be entirely distinct from those in primary depression.
To investigate, the research team studied 140 adults with asthma, measuring their blood BDNF levels and assessing symptoms of depression, anxiety, and daily physical activity using motion sensors. The results were eye-opening. Unlike in major depressive disorder, asthma patients with depressive symptoms had higher BDNF levels, which were linked to greater asthma severity. “These findings suggest that the biological underpinnings of depression in asthma may differ significantly from those in major depressive disorder,” explains Hiroshi Iwamoto, the study’s corresponding author and associate professor at Hiroshima University’s Graduate School of Biomedical and Health Sciences.
The study also highlighted the role of physical activity. Lower activity levels were associated with worse moods, indicating that the physical limitations of asthma may contribute to emotional distress. This raises a thought-provoking question: Is BDNF acting as a marker of physiological stress or inflammation in the body, rather than a direct cause of depression? If so, it could explain why depression in asthma doesn’t follow the same biological pattern as primary depression.
Another key takeaway is the importance of physical activity. Even after accounting for asthma severity, less active patients reported more depressive symptoms. This suggests that addressing both asthma and mental health together—rather than in isolation—could be the key to better patient outcomes.
“Our next step is to unravel the causal links between asthma severity, BDNF, and depressive symptoms through longitudinal and interventional studies,” Iwamoto adds. This research opens the door to a more integrated approach to treating asthma and depression, one that considers their unique biological interplay.
But what do you think? Does this study challenge how we understand and treat depression in asthma patients? Could physical activity play a bigger role in managing both conditions than we previously thought? Share your thoughts in the comments—we’d love to hear your perspective!
